Jaguar Animal Health (NASDAQ:JAGX) Announces Earnings Results

Jaguar Animal Health (NASDAQ:JAGX) issued its earnings results on Tuesday. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.26) by $3.90, FiscalAI reports. Jaguar Animal Health had a negative net margin of 341.90% and a negative return on equity of 1,194.94%. The firm had revenue of $3.24 million for the quarter, compared to analysts’ expectations of $4.21 million.

Jaguar Animal Health Stock Performance

JAGX stock opened at $0.41 on Tuesday. The company has a debt-to-equity ratio of 4.08, a quick ratio of 0.52 and a current ratio of 0.81. The stock has a market capitalization of $1.53 million, a price-to-earnings ratio of -0.01 and a beta of 0.27. Jaguar Animal Health has a 1 year low of $0.31 and a 1 year high of $15.48. The stock’s fifty day moving average is $0.57 and its two-hundred day moving average is $1.18.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Jaguar Animal Health to a “strong sell” rating in a report on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Jaguar Animal Health has an average rating of “Hold” and a consensus price target of $60.00.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.